Biotech TV



Latest Comments
image_pdfimage_print
 

Scythian CEO on the potential impact of cannabinoid drugs on traumatic brain injuries


August 29, 2017
| August 29, 2017 | 1 Comment

Jonathan Gilbert, CEO and Director, and David Schrader, COO of Scythian Biosciences Corp. (TSXV: SCYB) (“Scythian”) in an interview with […]


 

BlueOcean’s founder on astaxanthin – the “next wonder antioxidant”


March 14, 2017
| March 14, 2017 | 1 Comment

Sam Kanes, VP of Strategy and Investor Relations for BlueOcean NutraSciences Inc. (TSXV: BOC) in an interview with InvestorIntel’s CEO […]


 

InvestorIntel Interviews Dr. Zerbe of IntelGenx on Cialis deal


January 09, 2017
| January 09, 2017

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX |OTCQX: IGXT), discusses […]


 

IntelGenx CEO speaks to the potential impact of Montelukast on Alzheimers


January 03, 2017
| January 03, 2017

In this InvestorIntel interview, Dr. Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT) […]


 

André Godin on the IntelGenx license for Tadalafil erectile dysfunction dosing patent


December 06, 2016
| December 06, 2016

Andre Godin, Executive Vice President and CFO of IntelGenx Technologies Corp. (TSXV: IGX | OTCQX: IGXT), in an interview with […]


 

Aigner: how IntelGenX is forging ahead in fight against dementia


May 11, 2016
| May 11, 2016

IntelGenX Technologies Corp. (TSXV: IGX | OTCQX: IGXT) is a pioneer in innovative drug delivery technologies addressing unmet medical and […]